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Summary
Background: Although several clinical studies have evaluated plasma adiponectin
levels in response to chronic heart failure, little is known about the relation between
cardiac function and metabolic factors including adiponectin in patients with acute
myocardial infarction (AMI).
Methods and results: We analyzed 50 consecutive patients with AMI who had under-
gone successful coronary stent implantation. Echocardiography and blood sampling
were performed at 1 week and 6 months after AMI. Blood was analyzed with regard
to brain natriuretic peptide (BNP) and metabolic factors including plasma levels of
adiponectin, lipid proﬁle, and hemoglobin A1c (HbA1c). Plasma adiponectin levels
were signiﬁcantly increased at 6 months (7.3± 4.9g/ml) compared to those at 1
week (6.1± 3.7). BNP (from 156± 151 to 96± 124 pg/ml) signiﬁcantly decreased. In
addition, BNP at 6 months was positively correlated with plasma adiponectin levels
at 1 week (y = 0.019 x− 23.1, r = 0.537, P = 0.002), while BNP at 6 months was not
associated with maximal creatinine kinase after AMI. A multiple regression analysis
was performed to analyze the relationship between BNP at 6 months and metabolic
factors (plasma levels of adiponectin, lipid proﬁle, HbA1c, blood pressure, age,
sex, and body mass index) at 1 week after AMI. BNP at 6 months was most closely
correlated with plasma levels of adiponectin at 1 week (P = 0.045).
Conclusions: Among the metabolic factors examined, a higher adiponectin level at
1 week is the predictor of
months after AMI.
© 2008 Japanese College o
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Introduction
Metabolic syndrome (MetS), which consists of a
clustering of cardiovascular risk factors, such as
abdominal obesity, diabetes mellitus (DM), dys-
lipidemia, and hypertension, is associated with
increased coronary artery disease (CAD) morbidity
and mortality [1].
Adiponectin, which is a collagen-like plasma pro-
tein produced by adipose tissue, is known to play
an important role in the development of MetS. A
lower level of adiponectin is considered to be an
independent risk factor for CAD, and is associated
with patients with acute coronary syndrome (ACS)
[2] and coronary complex lesions in stable CAD
[3]. Adiponectin levels are lower in obese patients,
and obesity is also known to be a risk factor for
the development of chronic heart failure (CHF)
[4]. Lower adiponectin levels appear to be a risk
factor for CHF. Unexpectedly, recent studies have
indicated that a higher body mass index (BMI) is
associated with improved survival in patients with
CHF [5,6]. In addition, plasma adiponectin levels
are associated with an increased risk of mortality
in patients with CHF [7] and increase according to
the severity of CHF [8]. Thus, adiponectin may be
a critical risk factor for mortality and the severity
of CHF.
Much of themortality following acutemyocardial
infarction (AMI) results from cardiac dysfunction
after acute ischemia. Cardiomyocyte apoptosis has
been thought to play a key role in this pro-
cess. Shibata et al. reported that adiponectin
protects against the development of systolic dys-
function after AMI through its ability to suppress
cardiac hypertrophy and interstitial ﬁbrosis, and
also protects against myocyte and capillary loss
in adiponectin-deﬁcient mice [9]. Although many
clinical studies have evaluated plasma adiponectin
levels in response to CHF [5—8], little is known
about the relation between adiponectin and cardiac
dysfunction after AMI in humans. In this study, we
assessed the associations between cardiac function
and metabolic factors including plasma adiponectin
levels in patients with AMI.
Methods
Subjects and designThe subjects included 50 consecutive AMI patients
(men, 76%; age, 65± 11 years) who had initial coro-
nary angiograms and signiﬁcant coronary stenosis
(>50% luminal narrowing) as deﬁned by coronary
angiography and who were successfully implanted
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ith a stent. All of the enrolled patients received
spirin and ticlopidine. Follow-up coronary angiog-
aphy was performed at 6 months. There was
o cardiac event in any of the patients through-
ut the study. The ethics committee of Fukuoka
niversity Hospital approved this study and writ-
en informed consent was obtained from each
atient.
Patients did not have vascular disease (aorti-
is treated by prednisolone) or hepatic dysfunction
viral and nonviral, transaminases more than
hree times the normal value). Patients with low-
ensity lipoprotein cholesterol (LDL-C) ≥140mg/dl
r triglyceride (TG) ≥150mg/dl were diagnosed
s dyslipidemic. Patients with systolic or dias-
olic blood pressure (SBP or DBP) ≥140mmHg
r 90mmHg or who were under antihypertensive
reatment were considered to have hypertension.
atients who were being treated for diabetes mel-
itus (DM) or who had symptoms of DM and a fasting
lood glucose concentration ≥126mg/dl were con-
idered to have DM. Otherwise, the results of a 75-g
ral glucose tolerance test were used to diagnose
M.
lood sampling
lood sampling was performed at 1 week and 6
onths after AMI. Plasma levels of adiponectin,
rain natriuretic peptide (BNP), lipid proﬁle,
-reactive protein (CRP), fasting glucose, and
emoglobin A1c (HbA1c) were measured. When CRP
as less than 3mg/l, a high-sensitivity assay for
RP (hs-CRP) was also performed. The concentra-
ions of adiponectin in plasma were determined in
uplicate by speciﬁc enzyme immunoassays (R&D
ystems, Minneapolis, MN, USA) according to the
anufacturer’s instructions. At our laboratory, the
ntra- and inter-assay coefﬁcients of variation were
ach 5%.
ransthoracic ultrasound echocardiography
chocardiography was performed before coronary
ngiography upon hospitalization. An experienced
onographer obtained all echocardiographic data,
hich were interpreted by an experienced staff
chocardiographer. Comprehensive examinations
ere performed on all of the study patients,
ncluding M-mode, two-dimensional, conventional
oppler, and color Doppler echocardiography, at
he time of coronary angiography. Left ventricular
ass (LVM) was calculated as 1.04× {[LV internal
imension at end-diastole (LVDd) + intraventricular
eptal thickness (IVST) + LV posterior wall thickness
LVPWT)]3 − (LVDd)3}− 13.6 according to Devereux
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Table 1 Patient characteristics.
Age (years) 65 ± 11
Male (%) 76
BMI (kg/m2) 23.5 ± 3.5
Hypertension (%) 54
SBP (mmHg) 126 ± 25
DBP (mmHg) 76 ± 14
DM (%) 34
HbA1c (%) 5.9 ± 1.1
Fasting glucose (%) 99 ± 19
Dyslipidemia (%) 70
LDL-C (mg/dl) 126 ± 27
TG (mg/dl) 130 ± 73
HDL-C (mg/dl) 41 ± 11
Smoking (%) 68
Uric acid (mg/dl) 5.5 ± 2.1
Medication (%)
ARB 50
ACEI 0
CCB 14
-blocker 18
Diuretics 28
ISDN 20
Nicorandil 64
Statin 100
Number of vessels
1 (n) 26
2 (n) 14
3 (n) 10
Target vessel
RCA (n) 26
LCx (n) 2
LAD (n) 22
Stent implantation procedure
Types
Be stent (n) 1
Bx Velocity (n) 12
Duraﬂex (n) 3
Eepress 2 (n) 2
Multi-link (n) 20
Radius (n) 10
S660 (n) 1
Tsunami (n) 1
Length (mm) 20 ± 5
Diameter (mm) 3.3 ± 0.3
MIP (atm) 14 ± 3
BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; DM, diabetes mellitus; HbA1c,
hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol;
TG, triglyceride; HDL-C, high-density lipoprotein cholesterol;
ARB, angiotensin II receptor blocker; ACEI, angiotensin-
converting enzyme inhibitor; CCB, calcium channel blocker;
ISDN, isosorbide dinitrate; RCA, right coronary artery; LCx,diponectin and cardiac function
t al. [10], and the LVM index (LVMI) was adjusted
or body surface area.
tatistical analysis
tatistical analysis was performed using the Stat
iew statistical software package (Stat View 5; SAS
nstitute Inc., Cary, NC, USA). Categorical and con-
inuous variables were compared by a chi-square
nalysis and one-way analysis of variance followed
y post hoc Fisher’s PLSD test. The Spearman cor-
elation was used to examine the relation between
ontinuous variables. Multiple regression analysis
as used to assess the correlation of echocardio-
raphic parameters or metabolic factors to BNP at
months. Data are presented as the mean and stan-
ard deviation (SD). Signiﬁcance was considered to
e less than 0.05 unless indicated otherwise.
esults
atient characteristics
he baseline characteristics of the subjects are
hown in Table 1. The subjects consisted of 38
en and 12 women with a mean age of 65± 11
ears. Twenty-seven subjects had hypertension and
yslipidemia was present in 35 subjects. On stent
mplantation procedure, 8 types of stent were used
nd the average of length, diameter, and maximal
nﬂation pressure were 20± 5mm, 3.3± 0.3mm,
nd 14± 3 atm, respectively.
hanges in BP, plasma levels of biochemical
arameters
BP was signiﬁcantly reduced at 6 months com-
ared to those at 1 week, while there was no
hange in SBP (Table 2). LDL-C was signiﬁcantly
ecreased at 6 months and HDL-C was signiﬁcantly
ncreased at 6 months compared to those at 1
eek, while there was no change in HbA1c, fasting
lucose, and TG. Plasma adiponectin levels were
igniﬁcantly increased at 6 months compared to
hose at 1 week, and there were no differences in
lasma adiponectin levels at 1 week and 6 months
etween the presence and absence of DM, hyper-
ension, dyslipidemia, and treatment with statins
r angiotensin receptor blockers (ARBs) (data not
hown). In addition, the plasma adiponectin levels
n women tended to be higher than that in men at
week (P = 0.056), while there was no difference
t 6 months (P = 0.662) and no changes in the val-
es from 1 week to 6 months (P = 0.861). The levels
left circumﬂex artery; LAD, left anterior descending artery;
MIP, maximal inﬂation pressure.
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Table 2 BP, plasma levels of biochemical parameters at 1 week and 6 months.
1 week 6 month P-value
SBP (mmHg) 126 ± 25 123 ± 17 NS
DBP (mmHg) 76 ± 4 72 ± 9 0.049
HbA1c (%) 5.9 ± 1.1 5.8 ± 0.8 NS
Fasting glucose (%) 99 ± 19 100 ± 24 NS
LDL-C (mg/dl) 126 ± 27 98 ± 21 <0.001
TG (mg/dl) 193 ± 32 142 ± 89 NS
HDL-C (mg/dl) 41 ± 11 47 ± 11 <0.001
Adiponectin (g/ml) 6.1 ± 3.7 7.3 ± 4.9 0.009
BNP (pg/ml) 156 ± 151 96 ± 124 0.013
CRP (mg/l) 32 ± 46 2 ± 3 <0.001
A1c,
BNP,
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x− 23.1, r = 0.537, P = 0.002) (Fig. 1) and at 6
months (y = 0.009 x + 27.9, r = 0.379, P = 0.03), while
BNP at 6 months was not associated with maximal
creatinine kinase after AMI (r = 0.014, P = 0.941).SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb
TG, triglyceride; HDL-C, high-density lipoprotein cholesterol;
protein; NS, not signiﬁcant. When CRP was less than 3mg/l, a
of BNP and CRP were signiﬁcantly decreased at 6
months.
Changes in echocardiographic parameters
Among echocardiographic parameters, only IVST
at 1 week was signiﬁcantly lower than that at 6
months, whereas there were no changes in other
parameters (Table 3).
Simple regression analysis between BNP and
echocardiographic parameters at 6 months
Next, we analyzed the association between BNP
and echocardiographic parameters at 6 months.
Although there were no relationships between BNP
at 6 months or IVST and PWT at 6 months, BNP at 6
months was signiﬁcantly and positively correlated
with LVMI (r = 0.491, P = 0.003). In addition, BNP at
6 months was signiﬁcantly and positively correlated
with LVDd (r = 0.411, P = 0.030) and LVDs (r = 0.592,
P < 0.001) at 6 months, and BNP at 6 months was sig-
niﬁcantly and negatively correlated with ejection
Table 3 Echocardiographic parameters at post-stent
or 1 week and 6 months.
Parameters 1 week 6 month P-value
LVDd 51 ± 7 53 ± 7 NS
LVDs 36 ± 8 37 ± 8 NS
IVST 9 ± 2 8 ± 2 0.012
PWT 9 ± 2 9 ± 2 NS
EF 55 ± 12 57 ± 12 NS
LVM 214 ± 71 205 ± 69 NS
LVMI 131 ± 38 127 ± 43 NS
LVDd, left ventricular diastolic diameter; LVDs, left ven-
tricular systolic diameter; IVST, interventricular septum
thickness; PWT, posterior wall thickness; EF, ejection frac-
tion; LVM, left ventricular mass; LVMI, left ventricular mass
index; NS, not signiﬁcant.
F
A
xhemoglobin A1c; LDL-C, low-density lipoprotein cholesterol;
brain natriuretic peptide. hs-CRP, high-sensitive C-reactive
sensitivity assay for CRP (hs-CRP) was also performed.
raction at 6 months (r =−0.629, P < 0.001). Multi-
le regression analysis was performed to analyze
he relationship between BNP and echocardio-
raphic parameters (LVDd, LVDs, IVST, PWT, EF, LVM,
nd LVMI) at 6 months. BNP at 6 months was most
losely correlated with LVMI at 6 months (standard-
zed regression coefﬁcient = 1.012, P = 0.036).
orrelation between BNP at 6 months and
lasma adiponectin levels at 1 week and 6
onths
NP at 6 months was positively correlated with
lasma adiponectin levels at 1 week (y = 0.019igure 1 Correlations between BNP at 6 months after
MI and plasma adiponectin levels at 1 week (y = 0.019
− 23.1, r = 0.537, P = 0.002).
Adiponectin and cardiac function
Table 4 Multiple regression analysis for predicting
BNP at 6 months.
Factors Standardized
regression
coefﬁcient
P-value
Age 0.23 0.417
Sex −0.13 0.600
BMI (kg/m2) −0.03 0.899
SBP (mmHg) −0.07 0.826
DBP (mmHg) 0.26 0.446
HbA1c (%) 0.06 0.781
LDL-C (mg/dl) −0.19 0.353
TG (mg/dl) 0.17 0.438
HDL-C (mg/dl) −0.34 0.109
Adiponectin (g/ml) 0.51 0.045
BMI, body mass index; SBP, systolic blood pressure; DBP,
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rdiastolic blood pressure; HbA1c, hemoglobin A1c; LDL-C,
low-density lipoprotein cholesterol; TG, triglyceride; HDL-C,
high-density lipoprotein cholesterol.
ssociation between BNP at 6 months and
etabolic factors
ultiple regression analysis was performed to ana-
yze the relationship between BNP at 6 months and
etabolic factors (plasma levels of adiponectin,
ipid proﬁle, HbA1c, blood pressure, age, sex, and
MI) at 1 week (Table 4). BNP at 6 months was most
losely correlated with plasma levels of adiponectin
t 1 week (P = 0.045). Among the metabolic fac-
ors examined, a higher adiponectin level at 1 week
fter AMI was the strongest contributor to a higher
NP at 6 months after AMI.
iscussion
n this prospective study, we assessed the associa-
ion between BNP and echocardiographic parame-
ers or metabolic factors including adiponectin in
atients with AMI. The present study indicated that
NP at 6 months after AMI as a marker of cardiac
ysfunction was most closely associated with the
lasma adiponectin concentration at 1 week after
MI. A higher plasma adiponectin level might be a
redictor in the cardiac dysfunction after AMI.
Adiponectin has both anti-atherogenic and anti-
nﬂammatory properties. Plasma adiponectin levels
re negatively correlated with cardiovascular risk
actors [12] and are lower in obese patients [13].
ince obesity is also associated with increased LV
ilatation [14] and an increase in the incidence
f HF [4], higher plasma adiponectin levels should
e associated with a decreased risk of mortality
n patients with CHF. In addition, Kojima et al.
eported that low plasma adiponectin levels dur-
a
i
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ng post-AMI follow-up were associated with a poor
rognosis in men [11]. In fact, the experimental
tudies indicated that adiponectin exerts beneﬁ-
ial effects on the heart after pressure overload
r ischemia reperfusion injury in mouse models
15,16]. Moreover, adiponectin protects against the
evelopment of systolic dysfunction after MI in
diponectin-deﬁcient mice [9]. These clinical and
asic studies also suggest that adiponectin has car-
iovascular protective effects. In contrast to this
oncept, higher plasma adiponectin levels predict
ortality in patients with CHF. There is increasing
vidence that adiponectin plays an important role
n the development of CHF [5—7]. A recent study
eported a signiﬁcant association between plasma
diponectin levels and the severity of CHF [8]. Our
tudy also indicated that higher plasma adiponectin
evels might be a predictor of cardiac dysfunction
fter AMI. While our experiments were in progress,
noue et al. reported serum high molecular
eight adiponectin levels may serve as a pre-
ictor of future cardiovascular events in patients
ith CAD as well as a marker for severity of
AD [17]. With regard to the association between
diponectin and cardiac function, our results are
onsistent with those of Inoue et al., who reported
hat adiponectin level was negatively correlated
ith EF.
Since Shibata et al. [9] and Liao et al. [18] pro-
ided data to support the notion that adiponectin
rotected against the development of HF in
diponectin-deﬁcient mice, adiponectin is believed
o be essentially cardio-protective. In this study,
here was no signiﬁcant change in LVMI between
week and 6 months after MI. Progressive car-
iac hypertrophy may be compensatory at the
nitial stage of MI. Apoptosis in cardiomyocytes
ay contribute to the progression of HF after MI
19], and cardiac dysfunction is associated with
ncreased apoptosis in the infarct border zone after
I [20]. Since adiponectin overexpression attenu-
tes cardiac hypertrophy [15,18] (since myocardial
poptosis and infarct size were markedly enhanced
n adiponectin-deﬁcient mice [21]), the patients
ith higher BMI in the present study might show a
ompensatory increase in plasma adiponectin levels
o prevent hypertrophy. In support of this hypothe-
is, Nakamura et al. analyzed the changes in plasma
diponectin levels in CHF patients during early
ospitalization [8]. Plasma adiponectin levels can
apidly respond to acute changes in hemodynamics,
nd these levels were reduced in association with
mproved cardiac function within only 3.3 days.
Plasma adiponectin levels were clearly and posi-
ively related to BNP levels in this study. This ﬁnding
s consistent with a previous report [7]. Kistorp et
CO
p
A
c
o
A
W
T
R
[
[70
al. found a positive correlation between plasma
adiponectin levels and N-terminal (NT) proBNP lev-
els [7]. They hypothesized that natriuretic peptides
indirectly stimulate adiponectin through increased
lipid mobilization [22], although the mechanism
is not clear. Next, they also found an association
between NT-proBNP and BMI, while our data did
not show a relationship between BNP and BMI.
We cannot explain this discrepancy at this time.
Further studies are needed to address these two
issues.
The plasma adiponectin concentration is regu-
lated by the presence of DM, hypertension, and dys-
lipidemia. In addition, medications against CHF [23]
such as ARBs [24] have been shown to signiﬁcantly
increase the plasma adiponectin concentration.
Although many factors affect adiponectin levels,
there were no differences in plasma adiponectin
levels at 1 week and 6 months between the
presence and absence of DM, hypertension, dys-
lipidemia, or treatment with statins or ARBs in this
study. Plasma adiponectin levels are lower in men
than in women probably due to selective reduc-
tion by testosterone [25]. A recent study reported
that plasma adiponectin levels are associated with
future coronary events in men but not in women
[26]. The pattern of changes in plasma adiponectin
levels was also different between men and women
after AMI [10]. In this study, while the plasma
adiponectin concentration in women tended to be
higher than that in men at 1 week, there was no dif-
ference at 6 months and no changes in the values
from 1 week to 6 months. Moreover, we performed
a multiple regression analysis to analyze the rela-
tionship between BNP at 6 months and metabolic
factors including sex.
Although we only measured plasma adiponectin
levels as cytokines, tumor necrosis factor (TNF)-
 was reported to be increased in CAD and
CHF [27]. Adiponectin may counteract TNF-, and
adiponectin inhibits the release of TNF- from
adipose tissue [28]. Plasma adiponectin levels cor-
related with plasma levels of TNF- and BNP [8].
Other cytokines such as TNF-may bemore strongly
associated with survival in patients with CHF.
Study limitations
This study considered a limited number of patients
who underwent stent implantation after AMI. The
results of this study represent only a selected group
of patients and the sample size was relatively small,
which limited our ability to determine the signiﬁ-
cance of associations. To conﬁrm the results of this
study, a larger population needs to be examined.
[K. Kimura et al.
onclusions
ur results clearly show an association between
lasma adiponectin levels and BNP levels after AMI.
higher plasma adiponectin level at 1 week may be
ritical for predicting higher BNP levels as a marker
f cardiac dysfunction at 6 months after AMI.
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